Therapeutic pipeline for soft-tissue sarcoma

Introduction: Soft-tissue sarcomas (STS) represent a heterogeneous group of malignant tumors originating from connective tissues. Over recent years, this heterogeneity has led to a molecular breakdown of STS and subsequent use of targeted agents in several molecularly defined subgroups. After the in...

Full description

Saved in:

Bibliographic Details
Published in:	Expert opinion on pharmacotherapy Vol. 12; no. 16; pp. 2479 - 2491
Main Authors:	Cassier, Philippe A, Labidi-Galy, Sana Intidhar, Heudel, Pierre, Dutour, Aurélie, Méeus, Pierre, Chelghoum, Maria, Alberti, Laurent, Ray-Coquard, Isabelle, Blay, Jean-Yves
Format:	Journal Article
Language:	English
Published:	England Informa UK, Ltd 01.11.2011 Taylor & Francis
Subjects:	angiogenesis Angiogenesis Inhibitors Angiogenesis Inhibitors - therapeutic use Antineoplastic Agents Antineoplastic Agents - therapeutic use Cancer Enzyme Inhibitors Enzyme Inhibitors - therapeutic use Humans Insulin-Like Growth Factor I Insulin-Like Growth Factor I - antagonists & inhibitors Insulin-Like Growth Factor II Insulin-Like Growth Factor II - antagonists & inhibitors Life Sciences molecularly targeted agent mTOR Oncogene Protein v-akt Oncogene Protein v-akt - antagonists & inhibitors Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases - antagonists & inhibitors Platelet-Derived Growth Factor Platelet-Derived Growth Factor - antagonists & inhibitors Protein-Tyrosine Kinases Protein-Tyrosine Kinases - antagonists & inhibitors Receptor, IGF Type 1 Receptor, IGF Type 1 - antagonists & inhibitors Sarcoma Sarcoma - drug therapy Soft Tissue Neoplasms Soft Tissue Neoplasms - drug therapy soft-tissue sarcoma TOR Serine-Threonine Kinases TOR Serine-Threonine Kinases - antagonists & inhibitors
ISSN:	1465-6566, 1744-7666, 1744-7666
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Introduction: Soft-tissue sarcomas (STS) represent a heterogeneous group of malignant tumors originating from connective tissues. Over recent years, this heterogeneity has led to a molecular breakdown of STS and subsequent use of targeted agents in several molecularly defined subgroups. After the initial success of imatinib in gastrointestinal stromal tumors, several other compounds have shown promising activity in some but not all subgroups of sarcoma. Areas covered: This review discusses the rational and clinical results, when available, that support this subtype-directed approach. In the vast majority of cases, these agents have been tested only in patients with advanced disease; as chemotherapeutic agents are developed as non-histotype-specific therapies, they are not discussed here. The PubMed literature was searched using the terms 'sarcoma', 'angiogenesis', 'mTOR' and 'targeted agents'. Proceedings of the annual meeting of the American Society of Clinical Oncology as well as those of the Connective Tissue Oncology Society were also searched for relevant information. Expert opinion: Many agents are currently developed in a subtype-specific manner in STS and this represents a significant leap forward. However, much remains to be done to improve our understanding of the molecular biology of this heterogeneous group of diseases.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1465-6566 1744-7666 1744-7666
DOI:	10.1517/14656566.2011.604633